AZNCF - Apellis Is A Long-Term Name To Own Based On PNH Data Alone
- Apellis Pharmaceuticals is gearing up for potential approval of its PNH drug pegcetacoplan; the PDUFA date has been established for May 14, 2021.
- Pegcetacoplan achieved superior increase in hemoglobin levels in a head to heady study against Soliris. Upon FDA approval, pegcetacoplan may be used as alternative to Soliris and Ultomiris.
- Two pivotal phase 3 studies, DERBY and OAKS, using pegcetacoplan to treat patients with geographic atrophy will have a data release in Q3 of 2021.
- In a phase 1b study, geographic atrophy patients given pegcetacoplan had 52% slower lesion growth in the treated eye compared to the untreated eye.
For further details see:
Apellis Is A Long-Term Name To Own Based On PNH Data Alone